Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, natalizumab (Tysabri®) cannot be endorsed for use within NHS Wales as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for adult patients aged 18 years and over with high disease activity despite treatment with glatiramer acetate. |
||
|
||
Medicine details |
||
| Medicine name | natalizumab (Tysabri®) | |
| Formulation | 300 mg concentrate for solution for infusion | |
| Reference number | 2225 | |
| Indication | For use as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for adult patients aged 18 years and over with high disease activity despite treatment with glatiramer acetate. |
|
| Company | Biogen Idec Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 06/12/2013 | |
| Date of issue | 13/12/2013 | |